Back to the top

Collaboration

Collaborating Institutions

A movement cannot start without a significant commitment from all the people and institutions who choose to be involved. The five participating cancer centers have made a genuine commitment to collaborate across institutions. Together, we have the opportunity to make profound change.

Board of Directors

Dr Bill Nelson Johns Hopkins

William G. (Bill) Nelson, V, MD, PhD
Chairman of the Board, Break Through Cancer;
Marion I. Knott Director, the Sidney Kimmel
Comprehensive Cancer Center at Johns Hopkins

Lisa M. DeAngelis, MD

Lisa M. DeAngelis, MD
Physician-in-Chief and Chief Medical Officer,
Memorial Sloan Kettering Cancer Center

Giulio F. Draetta, MD, PhD

Giulio F. Draetta, MD, PhD
Senior Vice President and Chief Scientific Officer,
The University of Texas MD Anderson Cancer Center

Laurie Glimcher, MD

Laurie Glimcher, MD
President and Chief Executive Officer,
Dana-Farber Cancer Institute;
Director, Dana-Farber/Harvard Cancer Center

Alice Goodwin

Alice Goodwin
Trustee, Commonwealth Foundation for Cancer Research
(Photo courtesy of Richmond Times-Dispatch)

William H. Goodwin, Jr

William H. Goodwin, Jr
Trustee, Commonwealth Foundation for Cancer Research
(Photo courtesy of Richmond Times-Dispatch)

William C. Hahn, MD, PhD

William C. Hahn, MD, PhD
Executive Vice President and Chief Operating Officer, Dana-Farber Cancer Institute; Institute Member, Broad Institute

Susan Hockfield, PhD

Susan Hockfield, PhD
President Emerita, Massachusetts Institute of Technology

Tyler Jacks, PhD

Tyler Jacks, PhD
President, Break Through Cancer; Founding Director, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology

Elizabeth M. Jaffee, MD, FAACR, FACP

Elizabeth M. Jaffee, MD, FAACR, FACP
Cancer Center Deputy Director and Co-Director,
Gastrointestinal Cancers Program, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

David Jaffray, PhD

David Jaffray, PhD
Senior Vice President, Chief Technology and Digital Officer, The University of Texas MD Anderson Cancer Center

David A. Scheinberg, MD, PhD

David A. Scheinberg, MD, PhD
Chair, Molecular Pharmacology Program and Director, Experimental Therapeutics Center, Memorial Sloan Kettering Cancer Center

John Sherman

John Sherman
Trustee, Commonwealth Foundation for Cancer Research

MVHheadshot1 copy

Matt Vander Heiden, MD, PhD
Trustee, Director, Koch Institute for Integrative Cancer Research, Lester Wolfe (1919), Professor of Molecular Biology Professor of Biology

David M. Livingston, MD

David M. Livingston, MD
Special Advisor to the President, Break Through Cancer; Charles A. Dana Chair of Human Cancer Genetics, Dana-Farber Cancer Institute; Emil Frei III Distinguished Professor of Medicine, Harvard Medical School

Scientific Advisory Board

Cory Abate-Shen, PhD

Cory Abate-Shen, PhD
Chair, Department of Molecular Pharmacology and Therapeutics, Vagelos College of Physicians and Surgeons, Columbia University

John D. Carpten, PhD

John D. Carpten, PhD
Chair, Translational Genomics; Director, Institute of Translational Genomics, Keck School of Medicine, University of Southern California

Timothy Cloughesy, MD

Timothy Cloughesy, MD
Director, Neuro-Oncology Program; Director, Henry Singleton Brain Cancer Research Program, University of California, Los Angeles

Benjamin Haibe-Kains, PhD

Benjamin Haibe-Kains, PhD
Senior Scientist, Princess Margaret Cancer Centre, University Health Network; Associate Professor, Department of Medical Biophysics, University of Toronto

Patricia LoRusso, DO

Patricia LoRusso, DO
Associate Cancer Center Director, Experimental Therapeutics, Yale Cancer Center

Frank McCormick, PhD, FRS, DSc (Hon)

Frank McCormick, PhD, FRS, DSc (Hon)
Professor, Helen Diller Family Comprehensive Cancer Center; Department of Cellular and Molecular Pharmacology, University of California, San Francisco

Miriam Merad, MD, PhD

Miriam Merad, MD, PhD
Director, Precision Immunology Institute; Director, Mount Sinai Human Immune Monitoring Center, Icahn School of Medicine, Mount Sinai

dinahsinger

Dinah Singer, PhD
Bethesda, MD

Staudt_square

Louis M. Staudt, MD, PhD
Bethesda, MD

Alejandro Sweet-Cordero, MD

Alejandro Sweet-Cordero, MD
Director, Molecular Oncology Initiative, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco

E. John Wherry, PhD

E. John Wherry, PhD
Chair, Department of Systems Pharmacology and Translational Therapeutics; Director, Institute for Immunology, Perelman School of Medicine, University of Pennsylvania

The Break Through Cancer movement is built around a special formula

The formula starts with a community of innovative collaborators, then adds transformative funding from dedicated philanthropists, and research guidance from some of the most accomplished cancer experts in the world. Patients inspire us to find better solutions, faster. Biotech, pharma, and government partnerships will help us marshal the resources to drive discoveries to the clinic, and ultimately, to patients.

Not for a minute do we think we stand alone. In fact, Break Through Cancer can only imagine this world of multi-institutional collaboration because of essential, foundational support from the National Cancer Institute, and countless cancer research foundations, philanthropists, and companies who, over many years, have supported individual scientists and teams of researchers.

Make a difference

Break Through Cancer was created in February 2021 with an extraordinary matching gift of $250,000,000. Every gift to the Foundation supports groundbreaking cancer research and helps us to meet our matching commitment.

For questions about giving please email LMS@BreakThroughCancer.org